How does HRSA define the 340B orphan drug exclusion for DSH and cancer hospitals?

HRSA limits 340B discounts on orphan-designated drugs to uses outside their rare disease indication for disproportionate share hospitals and freestanding cancer centers. These entities must maintain detailed documentation proving that the drug was prescribed for a non-orphan condition, as auditors verify encounter-level data to confirm compliance.